• Azumiobodo hoyamushi Drug Efficacy in Ascidians

  2026-10-01

  Park and colleagues established a comparative in vitro and in vivo framework for evaluating treatments against Azumiobodo hoyamushi, the protozoan associated with soft tunic syndrome in cultured Halocynthia roretzi. Fumagillin showed moderate 24-hour antiparasitic activity, whereas formalin and chlorine dioxide produced the clearest reduction in parasite burden in experimentally infected ascidians.

• GKT137831 for Reliable Redox Cell Assays

  2026-09-30

  A scenario-based guide to using GKT137831 (SKU B4763) in cell viability, proliferation, and oxidative-stress assays. It covers solvent compatibility, dose selection, orthogonal readouts, interpretation of hypoxia responses, and practical vendor-selection criteria.

• Lisinopril Dihydrate: Research Workflows

  2026-09-29

  Lisinopril dihydrate provides a water-compatible, nanomolar ACE-inhibition tool for connecting renin–angiotensin signaling with cardiovascular and renal phenotypes. This guide translates its biochemical profile into practical workflows, selectivity controls, and troubleshooting strategies for hypertension, heart failure, myocardial infarction, and diabetic nephropathy studies.

• Crizotinib hydrochloride in Tumor Assembloids

  2026-09-29

  Use Crizotinib hydrochloride as a mechanistic probe in patient-derived gastric cancer assembloids, where matched stromal cells can reveal microenvironment-dependent changes in kinase response. This workflow combines ALK, c-Met, and ROS1 pathway interrogation with viability, imaging, and transcriptomic readouts for more informative cancer biology research.

• How In Vitro Assays Separate Cancer Drug Responses

  2026-09-28

  Hannah R. Schwartz’s dissertation shows why relative viability and fractional viability should not be treated as interchangeable measures of anticancer activity. By separating growth inhibition from cell killing and considering their timing, the work provides a practical framework for interpreting drug-response experiments more precisely.

• ARID1A-Dependent Networks in Melanoma Drug Resistance

  2026-09-28

  An integrative multi-omics study maps how ARID1A loss rewires early responses to BRAF/MAPK inhibition in BRAF V600E melanoma cells. Its findings connect persistent signaling and altered immune-related features to candidate resistance nodes, offering a framework for testing how chromatin-regulator loss shapes drug response.

• Miltefosine Workflows for Neutrophil Differentiation

  2026-09-27

  Miltefosine provides a practical tool for studying both acute PI3K/Akt signaling and neutrophil differentiation, but those questions require distinct exposure schedules and readouts. This guide translates recent Ras/MEK/ERK findings into a cautious, dose-finding workflow for hematology research.

• ECL Chemiluminescent Substrate Detection Kit for TNBC

  2026-09-26

  Translate TNBC pathway findings into a practical Western blot plan for tracking scarce Lin28B-axis proteins. The hypersensitive HRP substrate combines low-picogram detection capability with a signal window reported to persist for 6–8 hours under optimized conditions.

• Trelagliptin Succinate in Chondrocyte Workflows

  2026-09-25

  Use Trelagliptin succinate to test how DPP-4 inhibition intersects with inflammatory cartilage damage, not only glucose regulation. A practical IL-1β-challenged chondrocyte workflow pairs matrix and cytokine readouts with AMPK/SOX-9 pathway controls to distinguish protection from a simple change in cell viability.

• SD 169 (Indole-5-carboxamide): Evidence & Use

  2026-09-25

  SD 169 (indole-5-carboxamide) is a product-described, ATP-competitive p38α/p38β inhibitor for pathway research. Its reported diabetes and nerve-injury applications are promising research contexts, but the available product information does not establish dosing benchmarks or prove that SD 169 shares the separate dephosphorylation mechanism reported for selected p38α inhibitors.

• L-NAME Hydrochloride: Reading NO Beyond the Signal

  2026-09-24

  L-NAME Hydrochloride is a competitive NOS inhibitor for probing how nitric oxide contributes to vascular and inflammatory responses. This article explains how to distinguish direct enzyme inhibition from upstream inflammatory regulation, using recent chlorogenic acid–metal findings to sharpen assay interpretation.

• Dacarbazine Workflows for DNA-Damage Assays

  2026-09-24

  Build reproducible Dacarbazine experiments around fresh preparation, dose–response testing, and orthogonal readouts—not viability alone. This guide also explains why metabolism and supportive-care questions require separate experimental designs, with practical starting parameters for melanoma, lymphoma, and sarcoma models.

• Dacarbazine Workflows for Cancer DNA Damage Research

  2026-09-24

  Build more interpretable Dacarbazine experiments by controlling fresh preparation, exposure, solvent, and assay timing. This practical guide distinguishes in-vitro cytotoxicity from clinical treatment and supportive-care outcomes across melanoma, lymphoma, and sarcoma research.

• SERCA2 Dysfunction, FABP4, and Atherosclerosis

  2026-09-23

  The reference study identifies the calcineurin/FoxO1/FABP4 pathway as a mechanistic link between SERCA2 dysfunction, altered fatty acid handling, macrophage foam cell formation, and atherosclerosis. Its combination of a SERCA2 C674S knock-in model, metabolomics, macrophage assays, pharmacological inhibition, and partial FABP4 deficiency supports FABP4 as an intervention point rather than a passive disease marker.

• Beclin1, Ferroptosis, and DOX Liver Injury

  2026-09-22

  The reference study identifies Beclin1 as a potentially harmful regulator of doxorubicin-induced liver injury by linking excessive autophagy with ferroptotic lipid damage. Its results position DHODH as a downstream protective component and show how combined assessment of oxidative stress, iron handling, lipid peroxidation, and pathway markers can clarify mechanism.

8573 records 1/572 page Next 12345 下5页 Last page